Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Teva Releases Q2 2025 Aide Memoire

Jumat, 27 Juni 2025 - 03:41:22 Wib
Globenewswire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Jumat, 27 Juni 2025 - 03:23:49 Wib
Globenewswire

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Senin, 16 Juni 2025 - 22:13:00 Wib
Globenewswire

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Rabu, 04 Juni 2025 - 05:00:00 Wib
Globenewswire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Selasa, 03 Juni 2025 - 18:30:00 Wib
Globenewswire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Senin, 02 Juni 2025 - 03:23:09 Wib
Globenewswire

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Senin, 02 Juni 2025 - 03:21:53 Wib
Globenewswire

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Rabu, 28 Mei 2025 - 20:54:01 Wib
Globenewswire

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Rabu, 28 Mei 2025 - 03:46:55 Wib
Globenewswire

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Selasa, 27 Mei 2025 - 20:00:00 Wib
Globenewswire

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Jumat, 23 Mei 2025 - 21:21:12 Wib
Globenewswire

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Kamis, 22 Mei 2025 - 04:04:00 Wib
Globenewswire

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Kamis, 22 Mei 2025 - 04:02:24 Wib
Globenewswire

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Senin, 19 Mei 2025 - 16:00:00 Wib
Globenewswire

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Senin, 19 Mei 2025 - 16:00:00 Wib
Globenewswire

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Senin, 19 Mei 2025 - 02:26:40 Wib
Globenewswire

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

Selasa, 13 Mei 2025 - 00:57:04 Wib
Globenewswire

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

Rabu, 07 Mei 2025 - 18:30:00 Wib
Globenewswire

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Senin, 05 Mei 2025 - 21:43:51 Wib
Globenewswire

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

Selasa, 08 April 2025 - 03:52:58 Wib
Globenewswire

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Selasa, 08 April 2025 - 03:50:43 Wib
Globenewswire

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

Selasa, 01 April 2025 - 22:51:43 Wib
Globenewswire

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Jumat, 28 Maret 2025 - 21:48:52 Wib
Globenewswire

Teva Releases Q1 2025 Aide Memoire

Jumat, 28 Maret 2025 - 21:46:56 Wib
Globenewswire

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Rabu, 26 Februari 2025 - 11:16:38 Wib